Nikitas Georgakopoulos
About Nikitas Georgakopoulos
Nikitas Georgakopoulos is a Senior Scientist II at Valink Therapeutics, specializing in antibody discovery, cell biology, and immunology with a decade of experience in academia and the biotech and pharma industries.
Nikitas Georgakopoulos Senior Scientist II
Nikitas Georgakopoulos currently serves as a Senior Scientist II, bringing nearly a decade of experience in antibody discovery, cell biology, and immunology. He has traversed multiple sectors including academia, biotech, and pharma, providing him with a comprehensive understanding of the scientific landscape. His current work highlights his extensive expertise in developing novel therapeutic strategies.
Nikitas Georgakopoulos Education and Research
Nikitas Georgakopoulos earned his PhD from the University of Cambridge. His doctoral research involved pioneering studies on primary pancreatic 3D organoids. He focused on their tumorigenicity and immune rejection, utilizing advanced in vivo models such as humanized mice. This robust academic background underpins his current roles and achievements in the biotech industry.
Nikitas Georgakopoulos Professional Background
Before joining Valink Therapeutics, Nikitas Georgakopoulos worked for Takeda, where he led the development of a novel bispecific T cell engager programme. His role at Adaptate, which was later acquired by Takeda, involved designing and developing functional assays to enhance the performance of various immune engagers. This deep involvement in innovative therapeutic projects showcases his proficiency in immunology and cell biology.
Expertise in Antibody Discovery and Cell Biology
Nikitas Georgakopoulos specializes in antibody discovery, cell biology, and immunology. His nearly 10 years of experience span academia, biotech, and pharma industries, highlighting his versatile expertise. His work focuses on developing therapeutic strategies and improving immune function, underlining his significant contributions to the field.